Advanced Therapies: IL-1 Inhibitors

For some patients with recurrent pericarditis, standard medications like NSAIDs and prednisone are not enough to break the cycle of inflammation. In these cases, specialists may turn to IL-1 inhibitors, a class of medications known as biologics.

These drugs are often called “steroid-sparing” therapies because a primary goal is to allow you to safely taper off corticosteroids (like prednisone) while keeping the inflammation under control ^[1][2].

Targeting the Inflammation

As discussed earlier, idiopathic recurrent pericarditis is thought to involve the NLRP3 inflammasome, a cellular pathway that releases a powerful inflammatory messenger called IL-1 ^[3].

IL-1 inhibitors are targeted immunomodulators that block IL-1 signaling for this specific pathway. They target and neutralize the IL-1 molecules to help prevent them from triggering a full-blown flare ^[3][4].

Who Are These Medications For?

Because IL-1 inhibitors are targeted immunomodulators, candidacy depends on specialist judgment. They are typically considered for specific situations ^[5]:

• Colchicine Resistance: You have continued to have flares despite being on an adequate dose of colchicine ^[6].
• Corticosteroid Dependence: You are unable to lower your dose of prednisone without symptoms and inflammation returning ^[6][7].
• Objective Inflammation: While trials often required elevated CRP or specific MRI findings, in practice, doctors weigh your documented recurrences, treatment intolerance, comorbidities, and current disease activity ^[1][8].

Two Common IL-1 Inhibitors

There are two primary drugs currently used for this condition:

1. Rilonacept: This is FDA-approved specifically for recurrent pericarditis in adults and children 12 and older ^[5]. It is typically given as a weekly injection ^[1].
2. Anakinra: While generally used off-label for pericarditis, it is widely used and supported by clinical guidelines ^[9]. It is given as a daily injection ^[6].

The Caveat: The Risk of Relapse

A major clinical consideration with IL-1 inhibitors is that they treat the inflammation but may not permanently “cure” the underlying tendency. Research shows a high risk of relapse if the medication is stopped abruptly ^[6][1].

In the highly selected RHAPSODY trial, 74% of patients who were switched to a placebo after initially responding to rilonacept experienced a recurrence, compared to only 7% of those who stayed on the drug ^[1]. Similarly, 90% of patients in the small AIRTRIP trial relapsed after being switched from anakinra to a placebo ^[6].

Because of this risk, the optimal discontinuation approach remains individualized. One observational study found that patients who slowly increased the time between their rilonacept doses (dose-spacing) had a significantly lower recurrence rate (37%) than those who stopped cold turkey (82%) ^[10]. You should never alter injection intervals or stop the medication on your own.

Safety and Monitoring

IL-1 inhibitors are generally well-tolerated, but as immunomodulators, they require ongoing monitoring and specific safeguards ^[3]:

• Infection Risk: Because they dampen part of your immune system, you may be slightly more susceptible to infections. Contact your care team immediately if you develop a fever or symptoms of a serious infection. Avoid starting treatment during an active serious infection, and discuss any history of tuberculosis ^[3][11].
• Injection-Site Reactions: Redness, itching, or swelling at the spot where you injected the medicine is common. These usually become less frequent over time ^[3][12].
• Lab Work: Monitoring differs between drugs. Anakinra requires checks of kidney function and complete blood counts (specifically neutrophils), while rilonacept may require monitoring of blood counts and lipid (cholesterol) levels ^[13][14].
• Vaccines: Live vaccines are generally avoided during treatment, while non-live vaccines are usually handled individually and may have reduced responses. Talk to your doctor before any vaccinations.